E-marketing drives Rx site traffic: study

Share this article:
Online marketing has become an important driver of consumer traffic to prescription drug Web sites, results from a recent study indicate.

According to the findings of an analysis conducted in October by Internet behavior tracking firm comScore Pharmaceutical Solutions, approximately 31% of visitors first become aware of pharmaceutical Web sites or products through an online program.

One-fifth of all consumer online researchers reported they first became aware of a product via an online search, with individuals age 35-54 accounting for 23% of those visits.

Other online marketing programs such as banner ads were responsible for driving 10% of all traffic, the study found.

Depression was the top-ranked therapeutic area with 2.9 million visitors, the survey said. Bipolar disorder and insomnia ranked second and third with 1.8 million and 1.7 million unique visitors, respectively.

“Key players in depression, bipolar and insomnia have invested heavily in the online channel, through banner and search campaigns,” said Carolina Petrini, VP of comScore Pharmaceutical Solutions.

“Pharmaceutical companies are increasingly realizing the impact of online marketing on patients and prospects and are re-allocating their marketing funds accordingly.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...